Loading...
Market
What will be the market share of Eli Lilly's Zepbound vials in the U.S. weight-loss drug market by December 31, 2024?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Market research reports, pharmaceutical industry analyses, or major news outlets
Story
Eli Lilly Releases Tirzepatide Vials at 50% Discount to Boost Access and Supply
Aug 26, 2024, 03:00 PM
Eli Lilly has announced the release of single-dose vials of its popular weight-loss drug, Zepbound (tirzepatide), in the U.S. The vials are available in 2.5 mg and 5 mg doses, priced at $399 and $549 per month, respectively. This move aims to expand supply and accessibility, particularly for patients who cannot get the cost of the medicine reimbursed through their health insurance plans. The introduction of these vials is expected to ease supply constraints and provide a more affordable option compared to injection pens, which are priced higher.
View original story
Similar markets
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
1st • 25%
2nd • 25%
3rd • 25%
4th or lower • 25%
Eli Lilly gains significant market share • 25%
Eli Lilly maintains current market share • 25%
Eli Lilly loses market share • 25%
No significant change • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
More than $3 billion • 25%